{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Aspira Women's Health, Inc.
Is Aspira Women's Health, Inc. technically bullish or bearish?
As of May 1, 2025, the market trend is mildly bearish due to daily moving averages and monthly KST indicating bearish conditions, despite a mildly bullish weekly MACD and a bullish monthly RSI.
Who are in the management team of Aspira Women's Health, Inc.?
As of March 2022, the management team of Aspira Women's Health, Inc. includes Independent Chairman Mr. James LaFrance, President and CEO Ms. Valerie Palmieri, and Independent Directors Dr. Sandra Brooks, Ms. Nancy Cocozza, Dr. Veronica Jordan, and Mr. David Schreiber. They oversee the company's strategic direction and governance.
What does Aspira Women's Health, Inc. do?
Aspira Women's Health, Inc. develops and commercializes diagnostic tests for gynecologic diseases, particularly ovarian cancer. As of March 2025, it reported net sales of $2 million and a net loss of $2 million, with a market cap of $3.65 million.
How big is Aspira Women's Health, Inc.?
As of Jun 18, Aspira Women's Health, Inc. has a market capitalization of 3.65 million, with net sales of 9.31 million and a net profit of -10.32 million over the latest four quarters. Shareholder's funds are -2.56 million, and total assets amount to 5.49 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
